ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone201-478-5552
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.99 million
Profitability
Miscellaneous
Employees314
Next Earnings Date8/9/2019 (Estimated)
OptionableOptionable
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) issued its quarterly earnings results on Wednesday, March, 13th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.06. The biotechnology company earned $4.06 million during the quarter, compared to analyst estimates of $5.19 million. ADMA Biologics had a negative return on equity of 210.69% and a negative net margin of 370.27%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
7 brokers have issued 1 year price targets for ADMA Biologics' stock. Their predictions range from $7.50 to $16.00. On average, they anticipate ADMA Biologics' share price to reach $11.4167 in the next year. This suggests a possible upside of 142.9% from the stock's current price. View Analyst Price Targets for ADMA Biologics.
What is the consensus analysts' recommendation for ADMA Biologics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.
What are Wall Street analysts saying about ADMA Biologics stock?
Here are some recent quotes from research analysts about ADMA Biologics stock:
- 1. HC Wainwright analysts commented, "We note that Perceptive Credit Holdings is an investment entity of Perceptive Life Advisors, which is one of ADMA’s largest institutional shareholders. In our view, Perceptive’s extension of credit to ADMA underscores the investor’s confidence in the company." (2/21/2019)
- 2. Maxim Group analysts commented, "ADMA announced that FDA has accepted the BLA resubmission for RI-002, the company’s specialized IVIG immunoglobulin for Primary Immune Deficiency Disease (PIDD) and assigned a PDUFA date on April 2, 2019." (10/17/2018)
Has ADMA Biologics been receiving favorable news coverage?
Media coverage about ADMA stock has been trending positive on Thursday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ADMA Biologics earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include MeiraGTx (MGTX), Cellectis (CLLS), Twist Bioscience (TWST), Nightstar Therapeutics (NITE), Chiesi USA (CRTX), Vericel (VCEL), Precision BioSciences (DTIL), Osiris Therapeutics (OSIR), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), Adverum Biotechnologies (ADVM), Scholar Rock (SRRK), DBV TECHNOLOGIE/S (DBVT), Acorda Therapeutics (ACOR) and Mesoblast (MESO).
What other stocks do shareholders of ADMA Biologics own?
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)
- Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (3.19%), BlackRock Inc. (2.11%), Morgens Waterfall Vintiadis & Co. Inc. (1.24%), Northern Trust Corp (0.56%), Schonfeld Strategic Advisors LLC (0.49%) and Delek Group Ltd. (0.14%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond, Jerrold B Grossman and Lawrence P Guiheen. View Institutional Ownership Trends for ADMA Biologics.
Which institutional investors are selling ADMA Biologics stock?
ADMA stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Delek Group Ltd., Morgan Stanley, Wells Fargo & Company MN and Raymond James & Associates. View Insider Buying and Selling for ADMA Biologics.
Which institutional investors are buying ADMA Biologics stock?
ADMA stock was purchased by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Morgens Waterfall Vintiadis & Co. Inc., Jane Street Group LLC, Northern Trust Corp, ExodusPoint Capital Management LP, Burns J W & Co. Inc. NY, BlackRock Inc. and State of Wisconsin Investment Board. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond, Jerrold B Grossman and Lawrence P Guiheen. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $4.70.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $217.85 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.
What is ADMA Biologics' official website?
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
